Indivior Pharmaceuticals Inc·Healthcare

RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, is associated with lower relapse risk, fewer infection-related complications, and reduced healthcare utilization among people living with opioid use disorder (OUD). “Collectively, these studies highlight the benefits of sustained treatment with monthly injectable buprenorphine, including reduced relapse risk and fewer serious complications that often drive acute care use,” said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. “These findings also emphasize the importance of proactively identifying patients at risk of treatment discontinuation and supporting continued access to evidence‑based medications for opioid use disorder.”

Indivior Pharmaceuticals Inc. (INDV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

RICHMOND, Va., May 14, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: 2026 Jefferies Global Healthcare Conference – New York, NY – June 3 rd Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Wednesday, June 3rd and will also participate in a fireside chat on Wednesday, June 3rd at 11:05 a.m.

Indivior develops proprietary treatments for opioid dependence, generating revenue from specialty pharmaceuticals across global markets.

COCO, INDV and MPC stand out as momentum buys as investors apply Richard Driehaus' "buy high and sell higher" strategy.

Does Indivior Pharmaceuticals Inc. (INDV) have what it takes to be a top stock pick for momentum investors? Let's find out.
Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.
Healthcare
Drug Manufacturers - Specialty & Generic
1,030
2014-12-29
1.20